Surrey Heartlands

Joint Formulary & PAD

Hyoscine hydrobromide - Hypersalivation in children

You are here : Home > Formulary Search > Hyoscine hydrobromide - Hypersalivation in children

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Patches
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
Un
Restrictions / Comments :
Important
Off-label use. Transfer of prescribing responsibility to primary care after initiation and stabilisation of treatment - minimum of 1 month supply from the specialist team.
 

Status 2

Blue
Formulations :
  • Oral solution
  • Oral suspension
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
Restrictions / Comments :
Important
300mcg/5ml. Unlicensed formulation. Transfer of prescribing responsibility to primary care after initiation and stabilisation of treatment - minimum of 1 month supply from the specialist team

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Hyoscine hydrobromide
Indication :
Hypersalivation in children
Group Name :
Keywords :
excessive saliva, hypersialosis, drooling, sialorrhoea
Brand Names Include :
Scopoderm patch, Kwells
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0
Traffic Light Entries :
2

Other Indications

Below are listed other indications that Hyoscine hydrobromide is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Hypersalivation in children.

Committee Recommendations (1)

04 Dec 24 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Area Prescribing Committee agreed the traffic light status of this drug and indication as part of the Joint Formulary review.